Gill, D., & Burgess, S. (2020). Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes. Circ Genom Precis Med.
Chicago Style CitationGill, Dipender, i Stephen Burgess. "Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition On Cardiovascular Outcomes." Circ Genom Precis Med 2020.
Cita MLAGill, Dipender, i Stephen Burgess. "Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition On Cardiovascular Outcomes." Circ Genom Precis Med 2020.
Atenció: Aquestes cites poden no estar 100% correctes.